MEDPACE (MEDP) closed at $609.89, down 1.64 percent, underperforming the S&P 500's 0.02 percent loss. The stock had gained 4.14 percent over the preceding period, outpacing the Medical sector's 1.06 percent rise.
The company reports third-quarter earnings on Oct. 21. Analysts project earnings per share of $4.45, up 15.28 percent year-over-year, and revenue of $708.75 million, up 7.4 percent. For the full year, consensus estimates $17.54 in EPS, a 14.79 percent increase, and $2.84 billion in revenue, up 12.38 percent.
The risk: Medpace trades at a Forward P/E of 35.35—nearly double the Medical Services industry average of 17.86. Its PEG ratio of 2.77 exceeds the industry average of 1.67, signaling the market has priced in outsized growth. Any miss on guidance or a revenue slowdown could trigger a sharp correction. The stock's current Zacks Rank of #3 (Hold) reflects this tension between growth and valuation.
